To the Editor In a recent study,1 the partial nicotinic receptor agonist varenicline offered a viable cessation aid for smokers unwilling or unable to quit immediately but who were amenable to cigarette reduction prior to delayed attempts at full smoking cessation. Although the data from this randomized, double-blind, placebo-controlled multicenter study suggested benefit, marked heterogeneity in the study population was observed that warrants closer scrutiny to potentially identify specific subsets of patients who are the most or the least likely to benefit from such interventions.
R. Brooks Robey, Clay A. Block, Daniel J. O’Rourke. Varenicline for Smoking Reduction Prior to Cessation. JAMA. 2015;313(22):2285. doi:10.1001/jama.2015.4978